
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taurodeoxycholic Acid
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Shaperon
Deal Size : Inapplicable
Deal Type : Inapplicable
Hudson Therapeutics Starts Phase 2b Trial for NuGel
Details : NuGel, a first-in-class topical inflammasome inhibitor, which is being evaluated for the treatment of mild to moderate atopic dermatitis.
Product Name : NuGel
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 10, 2025
Lead Product(s) : Taurodeoxycholic Acid
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Shaperon
Deal Size : Inapplicable
Deal Type : Inapplicable
